Using Eμ-Myc lymphoma-derived cell lines, we performed a CRISPR/Cas9 screen with the mouse whole-genome “Yusa” sgRNA library [29], and utilised the MDM2 inhibitor nutlin-3a to activate TRP53 in a non-genotoxic manner. The gene discussed is TP53; the disease is lymphoma.